Causal forests find insufficient evidence for pancreatic treatment subgroups
Source check: Source checked. Not independent scientific confirmation.
Finding: In 130 pancreatic-cancer records, learned survival forests yielded overlapping patient-specific treatment-effect intervals across several priors. The cohort did not identify profiles with greater or smaller inferred radiotherapy benefit. This is model-dependent uncertainty, not evidence that treatment effects are identical.
Technology: Dirichlet-Tree Bayesian Causal Forest; Bayesian additive regression trees
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned tree partitions and outcome/treatment ensembles estimate conditional survival contrasts and their uncertainty.
- Test and result
- Retrospective TCGA cohort: 130 patients,36 receiving radiotherapy; censored accelerated-failure-time modeling with3,027 covariates and prior-sensitivity comparisons.
- Limitation / still unknown
- Nonrandomized treatment requires untestable no-unmeasured-confounding assumptions. Small sample, censoring and prior sensitivity limit heterogeneity inference. No individual treatment recommendation or proven average benefit; cohort largely overlaps an earlier analysis.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://arxiv.org/html/2610.26728v1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary v1 Methods3.1, application5.5 and full cohort/model/result appendixF.5; exact front/history/status..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.